Former China FDA Chief addresses challenges of innovative drugs in China
www.eastisread.com
Entry barriers in medical insurance and hospitals, reduced VC due to price caps, and inadequate basic research from lack of rewarding mechanisms, necessitate full-chain support for biopharmaceuticals.
Former China FDA Chief addresses challenges of innovative drugs in China
Former China FDA Chief addresses challenges…
Former China FDA Chief addresses challenges of innovative drugs in China
Entry barriers in medical insurance and hospitals, reduced VC due to price caps, and inadequate basic research from lack of rewarding mechanisms, necessitate full-chain support for biopharmaceuticals.